AFFiRiS and Frontier
AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China
December 22, 2021 04:00 ET | AFFiRiS AG
Frontier Biotechnologies obtains exclusive rights to develop and commercialize AFFITOPE® AT04 in Greater China Collaboration accelerates the global development of AFFiRiS potential first-in-class...
December 22, 2021 04:00 ET | AFFiRiS AG
前沿生物获得在大中华区开发与商业化AFFITOPE®AT04的独家权利合作旨在加快AFFITOPE®AT04主动免疫疗法作为同类首创新药的全球开发进程,推动其在大中华区的临床开发和生产落地 中国南京和奥地利维也纳, Dec. 22, 2021 (GLOBE NEWSWIRE) --...
AFFiRiS logo_white with blue globe.PNG
AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases
July 27, 2021 08:00 ET | AFFiRiS AG
AFFiRiS to receive AC Immune stock valued at USD 58.7 million in exchange for its portfolio of therapeutics targeting alpha-synuclein and USD 5 million in cashAFFiRiS to focus on partnering to further...
AFFiRiS logo_white with blue globe.PNG
AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of Clinical Pharmacology
May 27, 2021 05:00 ET | AFFiRiS AG
Repeated immunization with AFFITOPE® peptide active immunotherapy candidates AT04A and AT06A is safe, well-tolerated and induces a strong and long-lasting PCSK9-specific immune responseAT04A treatment...
AFFiRiS logo_white with blue globe.PNG
Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease to be presented at the 16th Annual Huntington's Disease Therapeutics Conference
April 27, 2021 03:00 ET | AFFiRiS AG
Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington’s disease pathologyHuman mtHTT transgenic mice treated with mAB C6-17 showed...